GLP-1s Are Shrinking More Than Your Waistline

Glucagon-like peptide-1 (GLP-1) receptor agonists — most prominently semaglutide (Ozempic, Wegovy) and the dual-incretin tirzepatide (Mounjaro, Zepbound) — were originally developed and approved on the strength of their effects on glycaemic control in type 2 diabetes and, subsequently, on body weight in obesity. Over the past three years, however, an expanding clinical and preclinical literature has begun to map a far broader portfolio of biological effects that extend well beyond appetite suppression and gastric emptying delay. This dispatch synthesises the most consequential of those emerging findings across four domains — addiction and reward signalling, systemic inflammation, cardiovascular and cardiac remodelling, and renal function — and discusses what they collectively suggest about GLP-1 receptor biology and the future trajectory of the drug class. The first and most-discussed novel finding concerns addictive behaviours. Multiple cohort studies, observational analyses of insurance-claims databases, and a growing number of small randomised investigations have reported that patients on GLP-1 receptor agonists experience reduced craving and reduced consumption across several substances of abuse — alcohol, nicotine, stimulants, and, in animal models, opioids. The mechanistic hypothesis centres on GLP-1 receptor expression in the mesolimbic reward circuitry: GLP-1 receptors are present on dopaminergic neurones in the ventral tegmental area, on neurones in the nucleus accumbens, and on glutamatergic projections from the prefrontal cortex into both regions. Activation of these receptors appears to dampen drug-induced dopamine release and reduce the conditioned reinforcing properties of multiple addictive substances. Several Phase 2 trials of semaglutide in alcohol use disorder are underway; preliminary results presented at major conferences in 2024 and 2025 have shown promising effect sizes, although peer-reviewed publication of full datasets is still pending in some cases. The second domain — systemic inflammation — has received particular attention because of its potential to explain effects observed across organ systems that are not directly metabolic. GLP-1 receptor agonists reduce circulating high-sensitivity C-reactive protein (hsCRP) by 25-40% in published trials, reduce IL-6 and TNF-alpha in some cohorts, and shift macrophage polarisation profiles in ways consistent with reduced chronic inflammation. The mechanism appears to involve direct GLP-1 receptor expression on macrophages and other immune cells, in addition to the indirect effects of reduced adiposity and improved glycaemia. The clinical consequences of this anti-inflammatory effect are still being mapped, but several investigators have proposed that inflammation reduction may underlie some of the cardiovascular benefits observed in landmark trials such as SUSTAIN-6, LEADER, and SELECT, where major adverse cardiovascular event (MACE) reduction has been larger than would be predicted by glycaemic and weight effects alone. The third domain concerns cardiac remodelling. The 2024 STEP-HFpEF and SUMMIT trials demonstrated functional improvement in patients with heart failure and preserved ejection fraction (HFpEF) on semaglutide and tirzepatide respectively — a patient population for which therapeutic options have historically been limited. Mechanistic work in animal models suggests GLP-1 receptor activation reduces cardiac fibrosis, improves diastolic function, and slows pathological hypertrophy through pathways that include direct GLP-1 receptor expression on cardiomyocytes and indirect effects mediated by reduced sympathetic tone and improved coronary microvascular function. The fourth domain — renal function — has been highlighted by the FLOW trial (semaglutide in chronic kidney disease in type 2 diabetes), which reported a 24% reduction in the composite primary kidney outcome relative to placebo. The mechanism is thought to combine reduced intraglomerular pressure, anti-inflammatory effects on the kidney directly, and the indirect benefits of improved glycaemia, blood pressure, and weight. Across all four domains, a recurring methodological theme is the difficulty of disentangling direct GLP-1 receptor effects from the secondary effects of weight loss, improved glycaemia, and reduced systemic inflammation. Future trial design will need to incorporate weight-loss-matched comparators (such as bariatric-surgery cohorts or combinations with non-GLP-1 weight-loss interventions) to clarify which effects are GLP-1-receptor-specific and which are downstream of metabolic improvement. Safety signals across the expanding indication landscape are largely consistent with the established profile of the class — gastrointestinal adverse events are dose-limiting, pancreatitis signals remain monitored but not statistically elevated in pooled analyses, and rare cases of medullary thyroid concern remain a class-wide warning. The dispatch concludes that the GLP-1 class has evolved over the past three years from a glucose-and-weight intervention into something closer to a broad metabolic-and-inflammatory modulator, with implications across multiple organ systems and disease domains. All discussion is for research education and does not constitute medical guidance.